75 results about "Ethanolamine synthesis" patented technology

The metabolic marker can be used for early diagnosis of heart failure, has the advantages of high sensitivity, rapidness, convenience and accurate and reliable result, provides a basis for clinical decision, provides a certain basis for subsequent fundamental research and clinical research, and has potential application and research values. The metabolic marker comprises one or more of 1-(4-nitrophenyl) piperidine, sphingolipid d19: 3 / 23: 0, phosphatidyl ethanolamine 16: 1e / 22: 5, phosphatidyl ethanolamine 16: 1e / 22: 6, sphingolipid d14: 0 / 22: 1, 3-phosphoglyceric acid, phosphatidylcholine 15: 0 / 20: 4, phosphatidylcholine o-16: 1 / 18: 0, phosphatidylcholine 14: 0e / 20: 1, phosphatidylcholine 17: 0 / 18: 5, betaine, phosphatidylcholine 15: 0 / 18: 2 and phosphatidylcholine 18: 5e / 20: 4.

The invention discloses an emulsifier for preparing a Pickering emulsion, the Pickering emulsion as well as a preparation method and application of the Pickering emulsion. The emulsifier of the Pickering emulsion is obtained by dissolving distearoyl phosphatidylcholine, cholesterol and distearoyl phosphatidyl ethanolamine-polyethylene glycol 2000 in ethanol, carrying out rotary evaporation to remove ethanol, then adding an antigen aqueous solution containing an antigen, continuing rotary evaporation to obtain liposome nanoparticles, heating the liposome nanoparticles with mannose in a water bath, and carrying out freeze drying. The Pickering emulsion is obtained by dispersing an emulsifier in water as a water phase, taking squalene as an oil phase, mixing the water phase and the oil phase, and homogenizing. The Pickering emulsion disclosed by the invention is prepared by taking antigen presenting cell targeted liposome nanoparticles as a raw material; and the antigen has excellent ion concentration characteristic, pH stability, temperature stability and storage stability, and can protect the integrity of the antigen.

The invention discloses injectable oxygen-carrying and medicine-carrying microbubble composite hydrogel with immunoregulation performance and a preparation method of the injectable oxygen-carrying and medicine-carrying microbubble composite hydrogel, and belongs to the field of tissue damage treatment. The preparation method comprises the following steps: carrying out a reaction on hyaluronic acid HA and dipalmitoyl phosphatidyl ethanolamine DPPE to construct a microbubble monomer DPPE-HA; the preparation method comprises the following steps: fully dissolving DPPC (dipalmitoyl phosphatidylcholine), DPPE-HA (dipalmitoyl phosphatidylcholine) and a therapeutic drug into a solvent, introducing oxygen and carrying out mechanical oscillation to obtain oxygen-carrying and drug-carrying microbubbles; the oxygen-carrying and drug-carrying microbubbles are uniformly doped into a vinyl modified natural polymer solution, and the oxygen-carrying and drug-carrying microbubble composite hydrogel is formed through photo-crosslinking. The obtained injectable microbubble hydrogel can be used for treatment of different tissue injuries, including wound repair and burn treatment, osteochondral injury repair, cardiovascular disease treatment and nerve injury repair, in addition, the injectable microbubble hydrogel can also be applied to the fields of cosmetic plastic surgery, skin regeneration and the like, and has a wide clinical application prospect.

The invention relates to the technical field of liposome preparation, and particularly discloses a nano liposome and a preparation method thereof.The method comprises the steps that distearoyl phosphatidyl ethanolamine, cholesterol, hydroxyl-terminated polyethylene glycol and mPEG-Hyd-PEG-SH are dissolved in a mixed solvent, and a lipid film is formed through rotary evaporation; hydrating with a PBS (Phosphate Buffer Solution) containing ammonium sulfate, and carrying out ultrasonic treatment to obtain primary emulsion; a doxorubicin solution is added for incubation, and drug loading is completed; the CD44 antibody and the drug-loaded liposome are coupled in a catalytic system, and are homogenized by a spiral microreactor. The problems of high immunogenicity, insufficient targeting, non-uniform particle size, uncontrollable drug release and complex preparation process of the existing PEG nano-liposome are solved, and the PEG nano-liposome has the advantages of low immunogenicity, high targeting, uniform and stable particle size, drug response release and easiness in large-scale production.

The application discloses a liposome of a FOXO1 inhibitor AS1842856 and a preparation method and application thereof. The liposome comprises the following raw materials: phospholipid, cholesterol, phospholipid PEG derivative and AS1842856; wherein the proportion of the phospholipid, the cholesterol and the phospholipid PEG derivative (for example, distearoyl phosphatidyl ethanolamine-polyethylene glycol 2000 (DSPE-PEG2000)) is preferably in the range of 10:0.2-2:0.5-5 (w / w); wherein the AS1842856 is wrapped in the liposome. The AS1842856 liposome of the application has excellent physical and chemical properties and has a wide application prospect in the field of fibrosis disease treatment.

The invention provides application of phosphatidyl ethanolamine in improving resistance of morchella to white mold. Experimental verification shows that exogenous addition of the phosphatidyl ethanolamine can enhance the resistance of the morchella to pseudomonas longispora, so that the resistance of the morchella to the white mold is improved, the development of the white mold is inhibited, the growth of a morchella sporocarp is promoted, and the application possibly has huge potential in the aspect of development of morchella white mold prevention and treatment products.

The invention belongs to the technical field of spectral analysis and detection, and particularly relates to a preparation method and application of a surface-enhanced Raman flexible substrate. The surface-enhanced Raman flexible substrate comprises a substrate, metal composite nano-particles with core-shell structures are uniformly distributed on the substrate, and the metal composite nano-particles are formed by coating metal nano-particles with stearoyl phosphatidyl ethanolamine-polyethylene glycol-sulfydryl. The preparation method of the flexible substrate comprises the following steps: preparing metal nanoparticles; dSPE-PEG-S-metal composite nano particles are prepared, and the DSPE-PEG-S-metal composite And preparing the DSPE-PEG-S-metal composite nano particle substrate. The single-layer metal composite nanoparticles which are uniformly and stably dispersed are arranged on the Raman flexible substrate, so that the phenomena of non-uniformity, easiness in agglomeration and the like of the substrate are effectively solved, the stability and the reliability of SERS signals are improved, and the Raman flexible substrate can be applied to exosome detection and analysis.

The invention relates to the technical field of adhesives, in particular to a modified phenolic resin adhesive and a preparation method thereof. The problems of excessive formaldehyde emission, long curing time, poor wear resistance, low bonding strength and poorer toughness of a phenolic resin adhesive are solved. By controlling the use amount of urea, urea reacts with formaldehyde to generate urea-formaldehyde resin, so that the content of free formaldehyde in the adhesive is reduced; the curing speed of the resin is increased by changing the dosage of the basic catalyst and the type and dosage of the curing agent; the chemical structure of the phenolic resin adhesive is changed by adding the cashew nut shell oil, and the crosslinking density and hardness of the phenolic resin adhesive are increased, so that the wear resistance of the adhesive is improved; by changing the dosage of formaldehyde and the type and dosage of the silane coupling agent, the binding force between the adhesive and a base material is enhanced, and the bonding strength is improved; vanadium pentoxide is modified by dioleoyl phosphatidyl ethanolamine, and the use amount of the modified vanadium pentoxide is changed, so that the toughness of the adhesive is improved.

The invention discloses a phospholipid compound for inhibiting beta-amyloid protein aggregation, and the chemical structural formula of the phospholipid compound is as follows: # imgabs0 #, and n is an integer greater than 2. Dioleoyl phosphatidyl ethanolamine molecules are modified by utilizing maleimide alkyl carboxylic acid and glutathione, so that the interaction between a phospholipid compound and amyloid protein can be effectively regulated and controlled, and the aggregation of the amyloid protein is delayed and even inhibited; the preparation method is simple, the reaction energy consumption is low, and the obtained phospholipid compound has good biocompatibility and is suitable for popularization and application.

The application relates to the field of medicine, in particular to a ROS (reactive oxygen species)-responsive liposome containing kaempferol and a preparation method and application thereof, to solve the problems of poor kaempferol efficacy and how to reduce the toxicity of PFOB in the prior art, realize stable kaempferol drug release, and improve the bioavailability. The liposome is a ROS-responsive liposome containing kaempferol, the liposome is a DTP liposome, the DTP liposome is a double-layered inner and outer layer with distearoyl phosphatidyl ethanolamine-polyethylene glycol as the outer shell of the liposome, a ketone thioacetal bond is located between the outer shells of the liposome, the drug loaded in the DTP liposome is a PEG-PFOB-PEG-kaempferol combination, namely a DTP@PPPK liposome, and the DTP@PPPK liposome can fully exert the efficacy and improve the safety.

The invention discloses a phototherapy nano-drug with mitochondrial / STAT3 protein double-site targeting. The phototherapy nano-drug is ATO / CR nano-particles formed by self-assembling a compound CR and atorvaquone under the action of distearoyl phosphatidyl ethanolamine-polyethylene glycol; the structure of the compound CR is shown as a formula I in the specification. The invention discloses an application of the phototherapy nano-drug with mitochondrial / STAT3 protein double-site targeting in preparation of drugs for treating tumors. The phototherapy nano-drug can target mitochondria and STAT3 protein in tumor cells through ATO, and can also passively target tumor sites through the high-permeability long-retention effect of nano-particles, so that more nano-therapeutic agents are enriched around tumors, and the curative effect is improved. The phototherapy nano-drug provided by the invention has good photothermal performance, can effectively enhance the PTT effect of gastric cancer, and exerts the tumor synergistic treatment ability by promoting cell apoptosis, inhibiting angiogenesis and hindering the cell cycle.

The invention relates to chlorotoxin-melittin nanoparticles as well as a preparation method and application thereof. The method comprises the following steps: weighing chlorotoxin, dissolving the chlorotoxin in a PBS buffer solution, adding 2-imino sulfane hydrochloride, fully mixing, and incubating at room temperature to form a CTX-SH solution; the preparation method comprises the following steps: weighing dimyristoyl phosphatidylcholine, adding a trichloromethane solution, uniformly mixing, then adding a cholesterol oleate solution and a phosphatidyl ethanolamine-polyethylene glycol 2000-maleimide solution, and sufficiently and uniformly mixing; drying the solution, resuspending with a PBS (Phosphate Buffer Solution), and fully dissolving by ultrasonic; adding a thiolated CTX-SH solution into the solution, incubating for 1-3 days, and carrying out ultrafiltration purification to form a CTX-NP nanoparticle solution; preparing a melittin solution, dropwise adding the melittin solution into the CTX-NP nanoparticle solution, incubating for 10-24 hours, and performing ultrafiltration purification. The invention has the advantages of targeting brain glioma, inhibiting the growth of in-situ brain glioma and improving the immunosuppressive microenvironment of brain glioma.

The application belongs to the technical field of pharmaceutical preparations, and discloses a nano-liposome with synergistic effect of double adjuvants and a preparation method and application thereof.The preparation method of the nano-liposome with synergistic effect of double adjuvants comprises the following steps: (1) mixing manganese chloride solution, cationic liposome, distearoyl phosphatidylcholine, distearoyl phosphatidyl ethanolamine-polyethylene glycol, cholesterol and a solvent to react, and evaporating to obtain a lipid film; (2) mixing the lipid film, human unmethylated oligodeoxynucleotide and water to heat, and filtering to obtain the nano-liposome with synergistic effect of double adjuvants.The obtained nano-liposome with synergistic effect of double adjuvants has excellent sustained release property.The obtained nano-liposome with synergistic effect of double adjuvants has stable physicochemical properties after being prepared into a nano-liposome vaccine adjuvant, and is convenient to store and transport.

The invention provides an anti-neuroinflammation medicine as well as a preparation method and application thereof. The anti-neuroinflammation medicine comprises an active component and lipidosome, the active component is an inhibitor 4-aminobenzoyl hydrazine of myeloperoxidase; the liposome is prepared from phospholipid, cholesterol and distearoyl phosphatidyl ethanolamine-thioketal-polyethylene glycol; the method comprises the following steps: weighing lipidosome and 4-aminobenzoyl hydrazine, dissolving, and carrying out rotary evaporation to obtain a lipid membrane; adding a phosphate buffer solution into the lipid membrane, stirring in a water bath, performing ultrasonic treatment, filtering, centrifuging and purifying to obtain the medicine, according to the active oxygen response-based liposome delivery system disclosed by the invention, 4-aminobenzoyl hydrazine is encapsulated in liposome to form a drug, and after the drug enters a brain inflammation microenvironment area of the Alzheimer's disease, the active oxygen can break a thioketal bond, so that local release of 4-aminobenzoyl hydrazine is triggered, targeted inhibition of myeloperoxidase is realized, and the drug delivery effect is improved. The oxidative stress level is reduced, the neuroinflammation is relieved, and the cognitive impairment is effectively improved.

The invention relates to the technical field of cosmetics, in particular to a sensitive skin repairing composition and application thereof.The mask liquid is prepared from chamomile oil, tea tree oil, radix gentianae extract, centella asiatica extract, 4-tert-butyl cyclohexanol, butanediol, phosphatidyl ethanolamine and cardiolipin. Phosphatidyl ethanolamine ester is modified, the weight ratio of all the components is adjusted, all the components in the composition are coordinated to play the optimal functions of diminishing inflammation, resisting allergy, easing pain and repairing, exogenous stimulation, nerve stress response and inflammatory response are reduced, meanwhile, the self-protection mechanism is strengthened, the skin barrier is repaired, and the skin repairing effect is achieved. The composition disclosed by the invention is free from preservatives, natural and safe, so that the product is milder and does not generate side effects such as dependence and drug resistance after being used for a long time.

The application belongs to the field of biological medicine, and discloses a nano-lipid preparation for loading perfluorohexane and an antioxidant, wherein the nano-lipid preparation is a core-shell structure, the core-shell structure takes a phospholipid liposome membrane layer as an outer shell, and perfluorohexane and the antioxidant loaded in the outer shell serve as an inner core; the phospholipid liposome membrane layer is made of hydrogenated lecithin, distearoyl phosphatidyl ethanolamine-polyethylene glycol 2000 and cholesterol; and the application discloses an application of the nano-lipid preparation for loading perfluorohexane and the antioxidant in preparation of a medicine for treating myocardial infarction. The nano-lipid preparation has a suitable particle size, can be passively targeted and enriched to a myocardial infarction site, is stable, has a high encapsulation efficiency, and has a simple administration mode; after the lipid preparation is taken by myocardial cells, oxygen and the antioxidant are released, the oxygen can relieve an anoxic condition of a myocardial ischemia site, and the antioxidant can reduce ROS damage, both of which play a synergistic role, improve the survival rate of ischemic myocardial cells, and improve heart function.

The invention relates to the field of synthetic phospholipids, and discloses a method for preparing phosphatidyl ethanolamine synthetic phospholipids under catalysis of phospholipase D. The method comprises the following steps: A, completely dissolving PC in an organic solvent to obtain a PC solution; b, adding ethanolamine into the buffer solution, and adjusting the pH value in an ice bath; c, mixing a metal salt solution with phospholipase D to obtain a fermentation enzyme solution, pouring a buffer solution containing ethanolamine, and uniformly mixing to obtain a water phase; d, mixing the PC solution with a water phase to uniformly disperse PC, and carrying out hydrolysis reaction to obtain a PE crude product reaction solution; e, standing for layering to obtain a water layer, extracting the water layer, and concentrating the obtained organic layer to obtain a PE crude product concentrate; f, refining to obtain a PE crude product I; g, performing column chromatography separation and vacuum concentration to obtain a PE crude product II with the purity not lower than 98%; f, drying to obtain a PE finished product. The method is simple in process, good in enzyme specificity, mild in reaction condition, environment-friendly, high in yield and beneficial to large-scale production of enterprises.

The invention relates to a hypoxia response paclitaxel prodrug, a nano preparation as well as a preparation method and application thereof. The paclitaxel prodrug is a paclitaxel prodrug small molecule modified by a nitro derivative; the preparation method comprises the following steps: preparing the nano-drug by self-assembly of the paclitaxel prodrug, co-assembly of the paclitaxel prodrug and the photosensitizer or co-assembly of the paclitaxel prodrug and the polymer distearoyl phosphatidyl ethanolamine methoxy polyethylene glycol, so as to realize efficient loading and delivery of the drug and responsive release of the focus site. The prodrug obtained by the invention has a chemical structure for optimizing a connecting bond, can reduce the toxic and side effects of paclitaxel and quickly respond to a hypoxic microenvironment, and realizes quick and efficient release of an active drug in a tumor microenvironment.

The invention provides a lipid nanoparticle. The lipid nanoparticle comprises a distearoyl phosphatidyl ethanolamine-polyethylene glycol derivative and a saturated fatty acid dimer as shown in a formula (I), wherein the mass ratio of the distearoyl phosphatidyl ethanolamine-polyethylene glycol derivative to the saturated fatty acid dimer is (10-30): (1-10). The saturated fatty acid dimer as shown in the formula (I) is delivered by adopting the distearoyl phosphatidyl ethanolamine-polyethylene glycol derivative, so that intracellular lipid accumulation and lipotoxicity effect can be induced, pyroptosis of tumor cells is promoted, systematic anti-tumor immune response is stimulated, and tumor growth is inhibited. More importantly, the lipid nanoparticles can enhance the sensitivity of liver cancer to PD-1 blocking treatment and significantly improve the combined treatment effect, no obvious toxic or side effect is observed, and the lipid nanoparticles show good clinical application prospects. (I).

The present application relates to a kind of biomimetic lung surfactant carrier, which is prepared from total fat and simulation peptide, in the total fat, the mass ratio of dipalmitoyl phosphatidylcholine, dipalmitoyl phosphatidylglycerol, dipalmitoyl phosphatidyl ethanolamine-polyethylene glycol 2000, cholesterol is 8-12:1:1:1;The lung surfactant simulation peptide is the simulation peptide of SP-B protein and / or the simulation peptide of SP-C protein.The biomimetic lung surfactant carrier has the advantages of high loading rate and high stability.The present application also relates to inhalation dosage form of drug for treating pulmonary arterial hypertension loaded by the biomimetic lung surfactant carrier, which makes the loaded drug obtain more uniform intra-pulmonary distribution, the inhalation drug is more close to natural lung surfactant in composition and physiological function, can delay the degradation of product, improve the utilization rate of drug, achieve good pulmonary arterial hypertension treatment effect.

The structural formula of the thymol-containing quaternary ammonium salt derivative is shown as (1), wherein R1 is 2-isopropyl-5-methylphenyl, ethyl or a benzene ring, R2 is 2-chloro-5-methylthiophene, 3-methyl-2-methoxycarbonyl furan, 4-methylnaphthalene and differently substituted benzyl, X-is Cl-and Br-, and n is equal to 3, 5, 7, 8 and 9. The preparation method of the drug-loaded antibacterial liposome comprises the step of jointly assembling hydrogenated soybean phosphatidylcholine, cholesterol hemisuccinic acid monoester, phosphatidyl ethanolamine and a target compound thymol-containing quaternary ammonium salt derivative into the drug-loaded antibacterial liposome. Part of the compounds have excellent antibacterial activity on Xanthomonas oryzae pv. Oryzae, Xanthomonas citri and Xanthomonas syringae pv. Kiwifruit. Meanwhile, the compound also has excellent biological activity on six fungi such as fusarium oxysporum and TMV viruses. A field test on Xoo shows that the protection effect of the drug-loaded antibacterial liposome is improved by 1.94 times, the treatment effect is improved by 1.56 times, and the drug-loaded antibacterial liposome shows remarkable pH-triggered release characteristics and colloidal stability. (1)

The application discloses a preparation method and application of copper porphyrin merocyanine nanoparticles converted from photodynamic and photothermal effects to chemical dynamic effects. The copper porphyrin merocyanine molecule is prepared through a meso-substitution reaction of hydroxyl copper porphyrin and heptamethine merocyanine, and nanoparticles are formed through co-assembly with distearoyl phosphatidylcholine and distearoyl phosphatidyl ethanolamine-polyethylene glycol. Under light conditions, the copper porphyrin merocyanine nanoparticles have good photodynamic and photothermal effects. During the light process, the gradual degradation of merocyanine leads to the depolymerization of nanoparticles, and the loose structure promotes the opening of the chemical dynamic performance, so that the switching from photodynamic / photothermal effects to chemical dynamic effects is realized. The copper porphyrin merocyanine nanoparticles prepared by the application have good application prospects in the fields of biological tracing, efficient tumor killing and the like.

The invention discloses a preparation method of chitosan surface modified extracellular vesicles, which specifically comprises the following steps: S1, dissolving chitosan in water, adjusting the pH value to be acidic, and completely dissolving the chitosan to obtain a chitosan solution with the concentration of 10mg / mL; s2, adding N-hydroxysuccinimide and 1-ethyl-(3-dimethylaminopropyl) carbodiimide hydrochloride into the solution obtained in the step S1, and uniformly stirring and fully mixing the N-hydroxysuccinimide and the 1-ethyl-(3-dimethylaminopropyl) carbodiimide hydrochloride; s3, the distearoyl phosphatidyl ethanolamine-polyethylene glycol 2000 is dissolved in formamide, and a distearoyl phosphatidyl ethanolamine-polyethylene glycol 2000 solution with the concentration being 1 mg / mL is prepared; s4, uniformly mixing the solution obtained in the step S2 and the solution obtained in the step S3, and stirring at room temperature for 12 hours; s5, transferring the mixed solution obtained in the step S4 into a dialysis bag with the specification of 3.5 KDa, and dialyzing in pure water for 24 hours; and S6, co-incubating the dialyzed solution obtained in the step S5 with an extracellular vesicle solution, and self-assembling to form the extracellular vesicle with the chitosan surface modified. The chitosan surface modified extracellular vesicles prepared by the method disclosed by the invention have relatively high encapsulation efficiency on hydrophobic drugs such as fucoxanthin and the like and relatively high stability in various environments. The method is suitable for embedding and delivering various bioactive substances, and has an important application prospect in the aspect of active substance delivery.

The invention discloses a biomarker for predicting the effect of improving blood glucose through diet intervention of a type 2 diabetes patient and application of the biomarker. The biomarker is composed of the following metabolite markers: 16 [alpha]-hydroxy dehydroepiandrostene-3-sulfate, 1-palmitoyl-2-linoleyl phosphatidylinositol glycerol (16: 0 / 18: 2), 1-oleoyl-2-arachidonyl phosphatidyl ethanolamine (18: 1 / 20: 4), 3-methoxy tyrosine and methyl succinyl carnitine, and the pH value of the biomarker is 7-8. The method is used for predicting the blood glucose improving effect of diet intervention of the type 2 diabetes patients, the prediction efficiency of traditional clinical indexes can be remarkably improved, the success rate of long-term blood glucose control is increased, accordingly, the treatment efficiency is improved, and application of precise medicine in type 2 diabetes management is achieved.

The invention discloses a novel oil-soluble micelle preparation. The component A comprises lecithin, soya bean lecithin, egg yolk lecithin, 1-palmitoyl-2-oleoyl lecithin, phosphatidylserine, phosphatidylinositol, phosphatidyl glycerol, cardiolipin, cephalin and dipalmitoyl phosphatidylcholine, and the component B comprises lecithin, soya bean lecithin, egg yolk lecithin, 1-palmitoyl-2-oleoyl lecithin, phosphatidylserine, phosphatidylinositol, phosphatidyl glycerol, phosphatidylcholine, cephalin and dipalmitoyl phosphatidylcholine; one or more of dipalmitoyl phosphatidyl ethanolamine and dipalmitoyl phosphatidyl ethanolamine; the component B comprises a component B1 and a component B2, and the component B1 comprises one or more of phytosterol, cholesterol, ergosterol, protopanoxadiol, protopanaxatriol, ganoderic acid, phytol, isophytol, retinol, andrographolide, paclitaxel, artemisinin and bisabolol; and the component B2 is prepared from one or more of 1, 2-hexanediol, ethylhexylglycerin, cyclohexyl glycerin, absolute ethyl alcohol and isosorbide dimethyl ether. The key point of the invention is to provide a low-cost formula and a low-cost preparation method for preparing the oil-soluble micelle preparation.

The invention provides a membrane phospholipid composition specific liposome for promoting eggshell mineralization and application thereof. The liposome membrane is prepared from the following components as raw materials: (a) core membrane phospholipid; (b) an acidic phospholipid and (c) a membrane stabilizing component; wherein the core membrane phospholipid comprises PC (Polycarbonate) and PE (Polyethylene); the acidic phospholipid is PS and / or PA; the membrane stabilizing component comprises at least one of methoxy polyethylene glycol modified phosphatidyl ethanolamine (DSPE-PEG), 1, 2-dimyristoyl-rac-glycerol-3-methoxy polyethylene glycol (DMG-PEG), 1, 2-dioleoyl-sn-glycerol-3-phosphoethanolamine-N-[methoxy (polyethylene glycol)] (DOPE-PEG), and cholesterol (Cholesterol). Through specific combination of core membrane phospholipids (PC and PE) and acidic phospholipids (PS and / or PA), an initial mineralization microenvironment in a living body is successfully simulated. In-vitro mineralization test results show that the liposome can effectively promote formation and growth of calcium carbonate crystal nucleuses, has excellent performance on interfaces of eggshell membranes, silicon wafers and the like, and proves universality and effectiveness.

The invention discloses a polycarbonate composite material as well as a preparation method and application thereof, and relates to the technical field of high polymer materials. The invention provides a polycarbonate composite material. The polycarbonate composite material is prepared from the following components in parts by weight: 70 to 95 parts of polycarbonate resin, 0.5 to 5.5 parts of polyolefin resin, 2 to 13 parts of phosphorus flame retardant, 1 to 9 parts of flexibilizer, 0.08 to 1.2 parts of hydrolysis-resistant agent and 0.04 to 0.52 part of lubricant, the lubricating agent is distearoyl phosphatidyl ethanolamine and / or dipalmitoyl phosphatidyl ethanolamine. The specific polyolefin resin, the hydrolysis-resistant agent, the lubricant and the like are selected, so that the PC composite material which has good appearance and can keep excellent mechanical properties and flame retardance in a high-temperature and high-humidity environment at the same time is prepared.

The invention provides a propylthiouracil liposome injection and a preparation method thereof. The propylthiouracil liposome injection comprises the following components: propylthiouracil, hydrogenated soybean lecithin, cholesterol, distearoyl phosphatidyl ethanolamine-polyethylene glycol 2000, alpha-tocopherol, a phosphate buffer solution and cane sugar. The preparation process comprises the steps of lipid film preparation, hydrated active drug loading, high-pressure homogenization, concentration and purification, sterilization and filtration, subpackaging and freeze-drying. The prepared propylthiouracil injection has the advantages of being fast in redissolution, good in stability, low in toxic and side effect, fast in clinical use effect and the like, is suitable for industrial large-scale production, can be used by patients who have hyperthyroidism emergency, coma, dysphagia and the like and cannot take oral liquid as the injection, and fills the blank in the current clinical treatment field.

The invention belongs to the technical field of biological medicine and food, and discloses a low-molecular-weight flammulina velutipes polysaccharide as well as a preparation method and application thereof. The flammulina velutipes polysaccharide with low molecular weight is prepared by preparing flammulina velutipes crude polysaccharide through an ultrasonic-assisted hot water extraction method and purifying through ion-exchange chromatography and gel chromatography. Through detection, the flammulina velutipes polysaccharide with low molecular weight is neutral polysaccharide, has alpha-type pyranoside, and is glucan which takes-> 4)-alpha-D-Glcp-(1-> and-> 4, 6)-alpha-D-Glcp-(1-> as main chains and alpha-D-Glcp-(1-> as side chains. Pharmacological experiments show that the flammulina velutipes polysaccharide with low molecular weight has a very strong anti-inflammatory effect on inflammation stimulated by lipopolysaccharide (LPS), and can play the anti-inflammatory effect by down-regulating the levels of dimethyl phosphatidyl ethanolamine and histamine.

The application relates to the field of biological medicine, and discloses a pH response phase transition sulfonic acid liposome for destroying a virus envelope structure as well as a preparation method and application thereof. The liposome is composed of dioleoyl phosphatidyl ethanolamine, (2,3-dioleoyl-propyl)-trimethylammonium chloride, oleic acid, sodium hexadecyl sulfonate and cholesterol. The liposome constructed by the application can neutralize viruses in the form of adhesion and wrapping of viruses in a high-pH environment in the early stage of virus infection, is endocytosed by cells, and is phase transitioned in lysosomes to realize intracellular inactivation of the viruses. In a low-pH microenvironment of inflammatory tissues caused by the late stage of virus infection, the liposome can directly destroy the virus envelope to realize virus inactivation through phase transition outside cells after adhesion of the viruses. Therefore, the liposome can realize effective killing of viruses in the early stage and the late stage of virus infection, has a spectrum antiviral effect, and has a wide application prospect.